FGF2 and neoplasm: The possible mechanisms of the failure of these anti-angiogenic treatments are the activation of alternative angiogenesis pathways involved in expression of bFGF, SDF-1 and VEGF and increased invasiveness of the tumor cells [5], [16], [17].